InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $3.520 0.11 (3.23%)+
Announcement
Release
30 Jan 2026 10:17AM
Price at Release
$3.410
Full Release
download
Summary
4DMedical Limited's Quarterly Activity Report and Appendix 4C for Q2 FY26 highlights significant advancements in their CT:VQ™ technology, following its FDA clearance in September 2025. The quarter saw rapid adoption by major U.S. academic medical centers and expanded distribution agreements with Philips, including Health Canada's approval, enhancing their market presence. Financially, the company reported a 31% increase in SaaS revenue, with a substantial cash balance of $206.2 million. A $150 million institutional placement was completed, reinforcing the company's financial strength to drive market penetration and maintain profitability goals.
Key Points
  • Strategic appointment of Julian Sutton as Chief Financial Officer.
  • 31% increase in SaaS revenue in H1 FY26.
  • Significant cost optimization achieved.
  • Rapid commercial adoption of CT:VQ™.
  • Successful $150 million institutional placement.
  • FDA and Health Canada clearances boost market potential.
  • Strong operational momentum with increased scan production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.